CN106943405B - Aripiprazole preparation and preparation method thereof - Google Patents

Aripiprazole preparation and preparation method thereof Download PDF

Info

Publication number
CN106943405B
CN106943405B CN201610006713.8A CN201610006713A CN106943405B CN 106943405 B CN106943405 B CN 106943405B CN 201610006713 A CN201610006713 A CN 201610006713A CN 106943405 B CN106943405 B CN 106943405B
Authority
CN
China
Prior art keywords
aripiprazole
parts
preparation
mixing
lactose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201610006713.8A
Other languages
Chinese (zh)
Other versions
CN106943405A (en
Inventor
刘伟超
丁云晖
谭波
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Zhongxi Pharmaceutical Co Ltd
Original Assignee
Shanghai Zhongxi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Zhongxi Pharmaceutical Co Ltd filed Critical Shanghai Zhongxi Pharmaceutical Co Ltd
Priority to CN201610006713.8A priority Critical patent/CN106943405B/en
Publication of CN106943405A publication Critical patent/CN106943405A/en
Application granted granted Critical
Publication of CN106943405B publication Critical patent/CN106943405B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention belongs to the field of drug research and development, and particularly relates to an aripiprazole preparation and a preparation method thereof. The aripiprazole preparation comprises the following raw materials in parts by weight: 2.0-15.0 parts of aripiprazole; 60.0-90.0 parts of a filler; 1.0-18.0 parts of a solubilizer; 1.0-7.0 parts of a disintegrating agent; 0.5-6.0 parts of a lubricant. The aripiprazole preparation of the invention is directly prepared without granulation and drying, so the aripiprazole preparation does not contain binding agents such as water, ethanol, povidone, hydroxypropyl cellulose and other organic solvents, the generation of aripiprazole hydrate and the subsequent associated polymorphic transformation are greatly reduced, the quantity of related substances can be obviously reduced, the dissolution property and stability are good, the bioavailability is high, and the individual difference is small.

Description

Aripiprazole preparation and preparation method thereof
Technical Field
The invention belongs to the field of drug research and development, and particularly relates to an aripiprazole preparation and a preparation method thereof.
Background
Aripiprazole chemical name 7- [4- [4- (2, 3-dichlorophenyl) -1-piperazinyl ] butoxy ] -3, 4-dihydro-2 (1 hydro) -quinolinone, a quinolinone derivative, was marketed by FDA approval in the united states at 11 months of 2002 for the treatment of schizophrenia.
When the aripiprazole crude crystals or the microcrystals of the insoluble drug are used for preparing the aripiprazole solid preparation, the obtained aripiprazole solid preparation is prepared by a traditional wet method, such as Chinese patents CN103860494 and CN 101574348B; in the preparation process of US20100004262a1, wet granules need to be dried, which is very easy to produce related substances and reduces the stability of solid preparations, thereby resulting in high content of related substances, and the requirements of the related substances in the 2015 pharmacopoeia are difficult to meet.
Therefore, aiming at the aripiprazole pharmaceutic preparation, an aripiprazole preparation and a preparation method thereof, which can overcome the defect that the stability of the existing preparation method is not ideal enough and can ensure various excellent performances, are urgently needed to be searched.
Disclosure of Invention
In order to overcome the problems of the prior art, the present invention aims to provide an aripiprazole formulation and a method for preparing the same.
In order to achieve the above objects and other related objects, the present invention adopts the following technical solutions:
compared with the prior art, the invention has the following beneficial effects:
the invention provides an aripiprazole preparation, which comprises the following components in parts by weight:
components Parts by weight
Aripiprazole 2.0-15.0 parts;
filler 60.0-90.0 parts;
solubilizer 1.0-18.0 parts;
disintegrating agent 1.0-7.0 parts;
lubricant agent 0.5-6.0 parts;
preferably, the aripiprazole preparation comprises the following components in parts by weight:
Figure BDA0000901614610000011
Figure BDA0000901614610000021
the aripiprazole can be selected from aripiprazole with various particle sizes, such as larger than 100 μm or smaller than 100 μm, which is conventional in the art.
Preferably, the aripiprazole is aripiprazole with a particle size below 50 μm, such as aripiprazole crystallites with an average particle size of 20-50 um or less than 20 μm. More preferably, less than 20 μm aripiprazole crystallites.
The aripiprazole crystallites used in the preferred embodiment of the invention are below 50 μm.
Preferably, the filler is selected from any one or combination of more of microcrystalline cellulose, pregelatinized starch, lactose, starch, mannitol, lactose complex.
The lactose complexes are state of the art, for example: lactose complex product capable of being used as Degumei group
Figure BDA0000901614610000022
80、
Figure BDA0000901614610000023
100、
Figure BDA0000901614610000024
Or lactose Complex products of the Germany JRS pharmaceutical excipients company
Figure BDA0000901614610000025
SMCC。
Preferably, the solubilizer is selected from any one or combination of sodium dodecyl sulfate, polyethylene glycol, poloxamer and polyoxyl 40 stearate. More preferably, the solubilising agent is selected from any one or a combination of sodium lauryl sulphate, poloxamer and polyethylene glycol.
Preferably, the disintegrant is selected from any one or combination of croscarmellose sodium, sodium starch glycolate and crospovidone.
Preferably, the lubricant is selected from any one or a combination of magnesium stearate, talc, sodium fumarate stearate and aerosil.
Preferably, the aripiprazole formulation may further comprise a colorant.
Further, the aripiprazole formulation may further include other pharmaceutically active ingredients as needed, and the other pharmaceutically active ingredients may be selected according to the conventional method in the art as long as they do not exert antagonistic action on aripiprazole.
In a second aspect of the present invention, there is provided a process for the preparation of the aforementioned aripiprazole formulation, which is a powder direct formulation process, comprising the steps of: directly tabletting or filling the mixture of the aripiprazole and other auxiliary materials into capsules.
Preferably, the method comprises the steps of:
sieving aripiprazole, adding filler, mixing, adding solubilizer and disintegrant, mixing, adding lubricant, mixing, and tabletting or encapsulating to obtain aripiprazole preparation.
Preferably, the method comprises the steps of:
sieving aripiprazole, adding filler in equal amount, mixing, adding disintegrant and solubilizer, mixing, adding lubricant, mixing, and tabletting or encapsulating to obtain aripiprazole.
Preferably, when the aripiprazole formulation contains aerosil, the method may comprise the steps of: mixing aripiprazole and aerosil and sieving, adding filler in equal amount and mixing, adding disintegrating agent and solubilizer, mixing, adding other lubricant, mixing, and tabletting or encapsulating to obtain aripiprazole preparation.
In a third aspect of the invention, there is also provided the use of the aforementioned aripiprazole formulation in the manufacture of a medicament for the treatment of schizophrenia.
In a fourth aspect of the present invention, there is also provided a method of treating schizophrenia, comprising the steps of: the aforementioned aripiprazole formulation is administered to the patient.
The specific amount may be selected by the physician according to the circumstances.
Compared with the prior art, the invention has the following beneficial effects:
(1) the aripiprazole preparation of the invention can obviously reduce the amount of related substances, and has good dissolution property and stability, high bioavailability and small individual difference. In one embodiment (according to the dissolution test method of aripiprazole solid formulation of the second pharmacopoeia 2015 edition) has an aripiprazole dissolution rate of not less than 85% after about 15 minutes; not less than 90% of the aripiprazole dissolution after about 30 minutes.
(2) The aripiprazole formulation of the present invention is prepared by a powder direct formulation method, and is directly prepared without granulation and drying, so that it does not contain binders such as water, ethanol, povidone, hydroxypropylcellulose and other organic solvents, and the production of aripiprazole hydrate and the subsequent associated polymorphic transformation are greatly reduced.
(3) The process for preparing aripiprazole formulations of the present invention requires fewer unit operations, uses less equipment, consumes less energy, is less space, is less time and labor, and has significant economic advantages. The process also avoids the use of organic solvents during formulation preparation, which may be toxic or difficult to handle due to environmental factors. The skilled person can easily master the equipment and conditions required for the blending step. Factors that may affect the blending step include, but are not limited to, the amount of raw materials, the physical characteristics of the raw materials, the equipment, and the mixing speed. The preparation method of the invention has simple operation, adopts dry preparation process, does not need drying, greatly reduces cost and is easy for industrialized production.
Detailed Description
Before the present embodiments are further described, it is to be understood that the scope of the invention is not limited to the particular embodiments described below; it is also to be understood that the terminology used in the examples is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention. Test methods in which specific conditions are not specified in the following examples are generally carried out under conventional conditions or under conditions recommended by the respective manufacturers.
When numerical ranges are given in the examples, it is understood that both endpoints of each of the numerical ranges and any value therebetween can be selected unless the invention otherwise indicated. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In addition to the specific methods, devices, and materials used in the examples, any methods, devices, and materials similar or equivalent to those described in the examples may be used in the practice of the invention in addition to the specific methods, devices, and materials used in the examples, in keeping with the knowledge of one skilled in the art and with the description of the invention.
The aripiprazole crystallites used in the examples of the present invention are 50 μm or less.
EXAMPLE 1 solid Aripiprazole formulation
The formula is as follows:
components Parts by weight
Aripiprazole 2.0
Microcrystalline cellulose 21.3
Pregelatinized starch 64.0
Croscarmellose sodium 3.0
Sodium dodecyl sulfate 6.8
Silica gel micropowder 2.0
Magnesium stearate 1.0
The preparation process comprises the following steps:
mixing aripiprazole and aerosil and sieving, then adding and uniformly mixing the same amount of microcrystalline cellulose and pregelatinized starch, adding croscarmellose sodium and sodium dodecyl sulfate, uniformly mixing, adding magnesium stearate into the mixture, mixing for 3 minutes, and tabletting or filling capsules to obtain the aripiprazole solid preparation.
EXAMPLE 2 solid Aripiprazole formulations
The formula is as follows:
Figure BDA0000901614610000041
Figure BDA0000901614610000051
the preparation process comprises the following steps:
sieving aripiprazole for later use, adding the same amount of microcrystalline cellulose and lactose gradually and uniformly mixing, adding carboxymethyl starch sodium and polyethylene glycol and uniformly mixing, adding talcum powder into the mixture, mixing for 5 minutes, and tabletting or filling capsules to obtain an aripiprazole solid preparation.
EXAMPLE 3 solid Aripiprazole formulation
The formula is as follows:
components Parts by weight
Aripiprazole 4.7
Microcrystalline cellulose 15.1
Lactose 60.3
Poloxamers 15.0
Sodium starch glycolate 1.0
Silica gel micropowder 2.0
Stearic acid fumaric acid sodium salt 2.0
The preparation process comprises the following steps:
mixing aripiprazole and aerosil and sieving, sequentially adding microcrystalline cellulose and lactose in equal amount, uniformly mixing, adding carboxymethyl starch sodium and poloxamer, uniformly mixing, adding sodium stearate fumarate into the mixture, mixing for 5 minutes, and tabletting or filling into capsules to obtain an aripiprazole solid preparation.
EXAMPLE 4 solid Aripiprazole formulation
The formula is as follows:
Figure BDA0000901614610000052
Figure BDA0000901614610000061
the preparation process comprises the following steps:
mixing aripiprazole and aerosil and sieving, adding starch in equal amount, adding cross-linked polyvinylpyrrolidone and poloxamer, mixing, adding pulvis Talci, mixing for 3 min, and tabletting or encapsulating to obtain solid aripiprazole.
EXAMPLE 5 solid Aripiprazole formulation
The formula is as follows:
components Parts by weight
Aripiprazole 14.9
Microcrystalline cellulose 6.9
Lactose 62.4
Polyoxyl 40 stearate 9.9
Croscarmellose sodium 2.0
Magnesium stearate 1.0
The preparation process comprises the following steps:
sieving aripiprazole for later use, then adding equal amounts of microcrystalline cellulose and lactose gradually and uniformly mixing, adding croscarmellose sodium and polyoxyl 40 stearate, uniformly mixing the mixture, adding magnesium stearate into the mixture, mixing for 3 minutes, and tabletting or filling capsules to obtain the aripiprazole solid preparation.
EXAMPLE 6 solid Aripiprazole formulation
The formula is as follows:
Figure BDA0000901614610000062
Figure BDA0000901614610000071
the preparation process comprises the following steps:
mixing aripiprazole and aerosil and sieving, adding lactose in equal amount, adding croscarmellose sodium and sodium dodecyl sulfate, mixing, adding magnesium stearate, mixing for 3 min, and tabletting or encapsulating to obtain solid aripiprazole.
EXAMPLE 7 solid Aripiprazole formulation
The formula is as follows:
components Parts by weight
Aripiprazole 4.8
Microcrystalline cellulose 23.0
Lactose 26.8
Mannitol 26.8
Polyethylene glycol 9.6
Sodium starch glycolate 3.8
Silica gel micropowder 3.8
Magnesium stearate 1.4
The preparation process comprises the following steps:
mixing aripiprazole and aerosil and sieving, adding microcrystalline cellulose, lactose and mannitol in equal amount, mixing, adding carboxymethyl starch sodium and polyethylene glycol, mixing, adding magnesium stearate, mixing for 3 min, and tabletting or encapsulating to obtain solid aripiprazole preparation.
EXAMPLE 8 solid Aripiprazole formulation
The formula is as follows:
Figure BDA0000901614610000072
Figure BDA0000901614610000081
the preparation process comprises the following steps:
mixing aripiprazole and aerosil and sieving, then uniformly mixing microcrystalline cellulose and lactose according to a proportion, adding the mixture into the aripiprazole and aerosil in equal amount and uniformly mixing, then adding croscarmellose sodium and poloxamer into the mixture, uniformly mixing, adding magnesium stearate into the mixture and mixing for 3 minutes, and tabletting or filling capsules to obtain the solid aripiprazole preparation.
EXAMPLE 9 solid Aripiprazole formulation
The formula is as follows:
components Parts by weight
Aripiprazole 4.7
Microcrystalline cellulose 16.9
Lactose 67.5
Polyethylene glycol 4.2
Sodium starch glycolate 2.8
Magnesium stearate 1.1
The preparation process comprises the following steps:
sieving the aripiprazole for later use, then uniformly mixing the microcrystalline cellulose and the lactose according to a proportion, adding the mixture into the mixture of the aripiprazole and the aerosil in an equivalent manner, uniformly mixing, then adding the carboxymethyl starch sodium and the polyethylene glycol into the mixture, uniformly mixing, adding the magnesium stearate into the mixture, mixing for 3 minutes, and tabletting or filling capsules to obtain the solid aripiprazole preparation.
EXAMPLE 10 solid Aripiprazole formulation
The formula is as follows:
Figure BDA0000901614610000082
Figure BDA0000901614610000091
the preparation process comprises the following steps:
mixing aripiprazole and aerosil and sieving, then adding microcrystalline cellulose and lactose in an equal amount in a progressive manner and mixing uniformly, then adding croscarmellose sodium and poloxamer into the mixture, mixing uniformly, adding sodium stearate fumarate into the mixture and mixing for 3 minutes, and tabletting or filling capsules to obtain the solid aripiprazole preparation.
EXAMPLE 11 solid Aripiprazole formulation
The formula is as follows:
components Parts by weight
Aripiprazole 4.4
Microcrystalline cellulose 23.5
Mannitol 55.9
Crosslinked polyvinylpyrrolidone 7.0
Poloxamers 3.2
Silica gel micropowder 5.0
Magnesium stearate 1.0
The preparation process comprises the following steps:
mixing aripiprazole and aerosil and sieving, then adding microcrystalline cellulose and mannitol in an equal amount in a progressive manner and mixing uniformly, then adding crosslinked polyvinylpyrrolidone and poloxamer into the mixture, mixing uniformly, adding magnesium stearate into the mixture and mixing for 3 minutes, and tabletting or filling capsules to obtain the solid aripiprazole preparation.
EXAMPLE 12 solid Aripiprazole formulation
The formula is as follows:
Figure BDA0000901614610000092
Figure BDA0000901614610000101
the preparation process comprises the following steps:
sieving aripiprazole for later use, then adding microcrystalline cellulose and lactose in an equal amount in a stepwise manner and mixing uniformly, then adding crosslinked polyvinylpyrrolidone and poloxamer into the mixture, mixing uniformly, adding magnesium stearate into the mixture and mixing for 3 minutes, and tabletting or filling capsules to obtain an aripiprazole solid preparation.
EXAMPLE 13 solid Aripiprazole formulation
The formula is as follows:
components Parts by weight
Aripiprazole 9.1
Lactose complexes 65.5
Poloxamers 18.0
Croscarmellose sodium 2.7
Silica gel micropowder 3.7
Magnesium stearate 1.0
The preparation process comprises the following steps:
mixing aripiprazole and aerosil and sieving, then adding lactose complex in equal amount and mixing uniformly, then adding croscarmellose sodium and poloxamer into the mixture, mixing uniformly, adding magnesium stearate into the mixture and mixing for 3 minutes, and tabletting or filling capsules to obtain solid aripiprazole preparation.
EXAMPLE 14 solid Aripiprazole formulation
The formula is as follows:
Figure BDA0000901614610000102
Figure BDA0000901614610000111
the preparation process comprises the following steps:
the aripiprazole is sieved for standby, then lactose and cellulose are added in equal amount and mixed uniformly, then carboxymethyl starch sodium and sodium dodecyl sulfate are added into the mixture, after mixing uniformly, magnesium stearate is added into the mixture and mixed for 3 minutes, and tabletting or filling capsules is carried out to obtain the solid aripiprazole preparation.
EXAMPLE 15 solid Aripiprazole formulation
The formula is as follows:
components Parts by weight
Aripiprazole 2.5
Lactose 63.0
Microcrystalline cellulose 22.5
Poloxamers 2.5
Sodium dodecyl sulfate 1.0
Sodium carboxymethyl starch 6.0
Silica gel micropowder 2.0
Magnesium stearate 0.5
The preparation process comprises the following steps:
mixing aripiprazole and aerosil and sieving, then adding lactose and cellulose in equal amount and mixing uniformly, then adding carboxymethyl starch sodium, poloxamer and sodium dodecyl sulfate into the mixture, mixing uniformly, adding magnesium stearate into the mixture and mixing for 3 minutes, and tabletting or filling capsules to obtain the solid aripiprazole preparation.
EXAMPLE 16 solid Aripiprazole formulation
The formula is as follows:
Figure BDA0000901614610000112
Figure BDA0000901614610000121
the preparation process comprises the following steps:
mixing aripiprazole and aerosil and sieving, then adding lactose and cellulose in equal amount and mixing uniformly, then adding carboxymethyl starch sodium, cross-linked polyvinylpyrrolidone and sodium dodecyl sulfate into the mixture, mixing uniformly, adding magnesium stearate into the mixture and mixing for 3 minutes, and tabletting or filling capsules to obtain the solid aripiprazole preparation.
EXAMPLE 17 solid Aripiprazole formulation
The formula is as follows:
components Parts by weight
Aripiprazole 9.1
Microcrystalline cellulose 31.1
Lactose 46.1
Poloxamers 8.2
Croscarmellose sodium 1.0
Silica gel micropowder 3.0
Stearic acid fumaric acid sodium salt 1.0
Magnesium stearate 0.5
The preparation process comprises the following steps:
mixing aripiprazole and aerosil and sieving, then adding microcrystalline cellulose and lactose in an equal amount in a gradually-increased manner and uniformly mixing, then adding croscarmellose sodium and poloxamer into the mixture, after uniformly mixing, adding sodium stearyl fumarate and magnesium stearate into the mixture and mixing for 3 minutes, and tabletting or filling capsules to obtain the solid aripiprazole preparation.
COMPARATIVE EXAMPLE 18 solid aripiprazole formulation (Wet granulation)
The formula is as follows:
Figure BDA0000901614610000131
the preparation process comprises the following steps:
filtering the aripiprazole raw material by a 80-mesh sieve for later use; sieving the rest adjuvants with 60 mesh sieve. The aripiprazole raw material and the internal auxiliary materials (povidone, lactose, microcrystalline cellulose and croscarmellose sodium) are mixed uniformly according to the prescription amount. Preparing wet granules on a wet granulator after adding water; the wet granules were then dried at 60 ℃ to a moisture content within 4%. After finishing granules, adding additional croscarmellose sodium, magnesium stearate and aerosil, mixing uniformly, and tabletting or filling capsules to obtain the aripiprazole solid preparation.
Example 19
The samples prepared in examples 1 to 18 were packed in high density polyethylene bottles, placed at 40 ℃. + -. 2 ℃ and relative humidity of 75%. + -. 5%, and sampled after 6 months of accelerated test to examine the content, dissolution rate and related substances.
The determination method of content, dissolution rate, related substances and content average comprises the following steps: according to the detection method of the content, dissolution rate, related substances and content of aripiprazole in the second part of the pharmacopoeia 2015 edition.
The results are shown in table 1:
TABLE 1
Figure BDA0000901614610000141
The results obtained in the above table 1 show that the hydrophilicity of the drug is greatly improved due to the mutual matching of the auxiliary materials added to the aripiprazole solid preparation of the embodiments 1-17 of the invention and the dry preparation process, and the dissolution rate of the drug is basically about 100%.
Because the invention adopts a dry preparation process, the content change is within 0.08 percent after the accelerated experiment is carried out for 6 months, and related substances are basically stabilized within 0.1 percent (meeting the standard of pharmacopoeia 2015 edition: the related substances are less than or equal to 0.2 percent). However, in comparative example 18 (wet preparation, patent CN103860494), after 6 months of acceleration, the content loss is about 0.3-1.0%, and the related substances are also increased to 0.33% (which does not meet the pharmacopoeia standard of 2015 edition).
Meanwhile, by the mutual matching of the auxiliary materials added in the aripiprazole solid preparation and the dry preparation process, the tablet content is also superior to that of the comparative example 18, and the difference in batches is small.
While the invention has been described with respect to a preferred embodiment, it will be understood by those skilled in the art that the foregoing and other changes, omissions and deviations in the form and detail thereof may be made without departing from the scope of this invention. Those skilled in the art can make various changes, modifications and equivalent arrangements, which are equivalent to the embodiments of the present invention, without departing from the spirit and scope of the present invention, and which may be made by utilizing the techniques disclosed above; meanwhile, any changes, modifications and variations of the above-described embodiments, which are equivalent to those of the technical spirit of the present invention, are within the scope of the technical solution of the present invention.

Claims (4)

1. The preparation method of the aripiprazole preparation is characterized in that the formula of the aripiprazole preparation is any one of the following: (1) the aripiprazole preparation comprises the following raw materials in parts by weight: 14.9 parts of aripiprazole; 6.9 parts of microcrystalline cellulose; 62.4 parts of lactose; 9.9 parts of stearic acid polyoxyl 40 ester as a solubilizer; 2.0 parts of disintegrant croscarmellose sodium; 1.0 part of lubricant magnesium stearate; (2) the aripiprazole preparation comprises the following raw materials in parts by weight: 4.7 parts of aripiprazole; 16.9 parts of microcrystalline cellulose; 67.5 parts of lactose; 4.2 parts of solubilizer polyethylene glycol; 2.8 parts of disintegrant sodium carboxymethyl starch; 1.1 parts of lubricant magnesium stearate; (3) the aripiprazole preparation comprises the following raw materials in parts by weight: 4.4 parts of aripiprazole; 27.6 parts of microcrystalline cellulose; 55.0 parts of lactose; 6.1 parts of solubilizer poloxamer; 4.0 parts of disintegrant crosslinked polyvinylpyrrolidone; 1.0 part of lubricant magnesium stearate; the aripiprazole is aripiprazole with the average particle size of below 50 μm; the preparation method of the aripiprazole preparation comprises the following steps: sieving aripiprazole, sequentially adding microcrystalline cellulose and lactose in equal amount and mixing, adding disintegrating agent and solubilizer and mixing, adding magnesium stearate as lubricant and mixing, and tabletting or encapsulating to obtain aripiprazole preparation.
2. A process for preparing aripiprazole formulation according to claim 1, wherein the average particle size of said aripiprazole is 20-50 um.
3. A process for preparing an aripiprazole formulation according to claim 1, wherein said aripiprazole is an aripiprazole crystallite having a mean particle size of less than 20 μm.
4. Use of an aripiprazole formulation prepared according to the process of any one of claims 1 to 3 for the preparation of a medicament for the treatment of schizophrenia.
CN201610006713.8A 2016-01-06 2016-01-06 Aripiprazole preparation and preparation method thereof Active CN106943405B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610006713.8A CN106943405B (en) 2016-01-06 2016-01-06 Aripiprazole preparation and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610006713.8A CN106943405B (en) 2016-01-06 2016-01-06 Aripiprazole preparation and preparation method thereof

Publications (2)

Publication Number Publication Date
CN106943405A CN106943405A (en) 2017-07-14
CN106943405B true CN106943405B (en) 2021-04-06

Family

ID=59465883

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610006713.8A Active CN106943405B (en) 2016-01-06 2016-01-06 Aripiprazole preparation and preparation method thereof

Country Status (1)

Country Link
CN (1) CN106943405B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109984999B (en) * 2019-04-28 2021-12-24 重庆仁泽医药科技有限公司 Pharmaceutical composition and preparation method and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101351193A (en) * 2006-01-05 2009-01-21 特瓦制药工业有限公司 Dry formulations of aripiprazole
CN102850268A (en) * 2011-06-27 2013-01-02 上海中西制药有限公司 Aripiprazole I-type crystallite, aripiprazole solid preparation and preparation methods thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101351193A (en) * 2006-01-05 2009-01-21 特瓦制药工业有限公司 Dry formulations of aripiprazole
CN102850268A (en) * 2011-06-27 2013-01-02 上海中西制药有限公司 Aripiprazole I-type crystallite, aripiprazole solid preparation and preparation methods thereof

Also Published As

Publication number Publication date
CN106943405A (en) 2017-07-14

Similar Documents

Publication Publication Date Title
CN103550165B (en) A kind of pharmaceutical composition and preparation method thereof containing razaxaban
CA2785857A1 (en) Production method of solid preparations and the solid preparations produced by the method
CN107582531B (en) Rivaroxaban solid preparation and preparation method thereof
CN113939289A (en) Oral solid tablet containing Bruton's tyrosine kinase inhibitor and preparation method thereof
EP2799072A1 (en) Solid pharmaceutical composition comprising an antibiotic from the quinolone family and method for the production thereof
CN105412036A (en) Brexpiprazole orally disintegrating tablets
CN102952144A (en) Crystal forms of asenapine maleate, and preparation method and medical composition thereof
WO2017028660A1 (en) Pharmaceutical composition containing quinoline derivative or salt thereof
CN106943405B (en) Aripiprazole preparation and preparation method thereof
EP2359816B1 (en) Aripiprazole formulations
JP2017190325A (en) Amorphous solifenacin-containing preparation with improved chemical stability
CN103083273A (en) Imatinib mesylate tablet cores, coated tablets, and preparation method thereof
EP3378479B1 (en) Method for preparing pharmaceutical composition comprising quinoline derivative or salt thereof
WO2019080830A1 (en) Pharmaceutical composition containing quinoline derivative
CN106377514A (en) Lurasidone hydrochloride dispersible tablet
CN103083326A (en) Ulipristal acetate medicine composition
CN111888477B (en) Bedaquinoline pharmaceutical preparation
CN107913254A (en) A kind of ticagrelor dispersible tablet and preparation method thereof
CN108354909B (en) Pharmaceutical composition containing quinoline derivative or salt thereof
CN112057427A (en) Oral solid tablet containing Bruton's tyrosine kinase inhibitor and preparation method thereof
CN112107554A (en) Betricitaban capsule and preparation method thereof
CN112704740B (en) Montelukast resin compound and preparation method and application thereof
KR102481517B1 (en) Pharmaceutical Formulation
TWI586379B (en) Method of preparing very slightly soluble drug with solid dosage form
TWI732762B (en) Oral sustained release formulation

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant